with cardiac valve calcification in a population of 970 individuals with prevalent cardiovascular disease (CVD), most with normal kidney function (12 ) . In another study, among 382 older whites, low fetuin-A concentrations were associated with greater CAC measured on computed tomography (CT) approximately 5 years after fetuin-A measurement (13 ) . Two small studies (n ϭ 64 each) evaluated patients referred for angiography and reported no association between fetuin-A and CAC severity (14, 15 ) .
Relationships of fetuin-A with vascular disease are made more complex by its additional actions on insulin resistance. Fetuin-A inhibits the insulin receptor and induces insulin resistance in vitro and in animal models (16 -20 ) . Whereas low fetuin-A is associated with arterial calcification and CVD events in ESRD (6 -9 ) , high fetuin-A has been associated with insulin resistance (21) (22) (23) and greater risk for diabetes (24, 25 ) . Thus, fetuin-A may exert simultaneous competing effects on CVD, and these effects may differ by diabetes status.
We evaluated the association of serum fetuin-A concentrations with the prevalence, severity, and incidence of CAC in a large community-living population without clinical CVD. As a secondary aim, we evaluated the heterogeneity in these associations by sex, race, and diabetes status.
Methods

PARTICIPANTS
Between 2000 and 2002, the Multi-Ethnic Study of Atherosclerosis (MESA) recruited 6814 individuals, aged 45-84 years, who self-identified as Caucasian (white), African-American, Hispanic, or Chinese and were free of clinical CVD. Participants were recruited from 6 US communities: Baltimore, MD; Chicago, IL; Forsythe County, NC; Los Angeles, CA; North Manhattan and the Bronx, NY; and St. Paul, MN. Exclusion criteria included physician-diagnosed CVD or heart failure, pregnancy, active treatment for cancer, residency in a nursing home, cognitive impairment, weight Ͼ300 pounds, or having received a CT scan in the preceding year (26 ) . The institutional review boards of all participating centers, the coordinating center, and University of California San Diego approved the study, and all participants provided written informed consent.
All participants underwent chest CT scans for assessment of CAC at their baseline examination and were invited to return for follow-up CT scans. Half had their follow-up CT scans performed at the second study visit and the remainder at the third visit (approximately 3 years after baseline). Timing of the follow-up CT was assigned at the time of the baseline visit by computer random number generator. To maximize statistical power to detect incident CAC, this study enrolled all 2774 individuals who had both the baseline and third-visit CT scan. From these, we excluded 224 individuals with insufficient serum for fetuin-A measurement and 93 participants with missing covariate data, resulting in a final analytic sample of 2457 participants for this analysis.
FETUIN-A
Venous blood samples were collected at the baseline MESA examination and serum was frozen at Ϫ70°C. In 2009, specimens were thawed and we measured fetuin-A at the Clinical Chemistry Laboratory at the University of Maryland with a human ELISA kit (EKISA, Epitope Diagnostics). The assay uses a 2-site sandwich technique with polyclonal antibodies that bind different epitopes of human fetuin-A. We measured serum samples twice in each participant and averaged the results. Specimens were run in random order without reference to CAC prevalence. As an internal control, we ran pooled serum samples on each ELISA plate and noted an abrupt drift in mean concentrations after approximately half of the measurements had been completed. Thus, fetuin-A measurements performed after that point were recalibrated to mean of pooled serum measurements before the occurrence of the drift. The lower limit of detection of the assay is 0.05 mg/L. We used duplicate measurements in all participants to assess the intraassay CV across the whole spectrum of observed fetuin-A concentrations (range 0.20 -0.94 g/L); the mean intraassay CV was 3.0%. We used pooled serum specimens to assess the mean interassay CVs across the 85 ELISA plates, which showed a mean interassay CV of 5.3% and 4.8% at fetuin-A concentrations of 0.29 and 0.58 g/L, respectively.
CAC
We measured CAC with either an Imatron C-150XL electron beam CT scanner (GE-Imatron) or a multidetector CT scanner as described (27 ) . CT scans were done twice at each visit, and identical protocols were used at the baseline and third visit. An expert committee developed a scanning protocol to standardize scan acquisition across the 2 slightly different technologies, and data quality was equivalent between CT scan techniques (28 ) . Images were read centrally at the Harbor-UCLA Research and Education Institute (Torrance, CA) (27 ) .
OTHER MEASUREMENTS
Prevalent diabetes mellitus was defined as fasting blood glucose Ն126 mg/dL (7.0 mmol/L) or use of hypoglycemic medications or insulin. We measured resting blood pressure 3 times with participants in the seated position by use of a Dinamap model Pro 100 sphygmomanometer (Critickon, General Electric), using the mean of the last 2 measurements. The medications used by study participants were recorded by study personnel. Smoking status was categorized as current, former, or never. We measured height and weight with participants wearing light clothing and no shoes and calculated body mass index (in kg/m 2 ). Concentrations of total cholesterol, HDL cholesterol, and triglycerides were measured with fasting (8-h) morning samples. LDL cholesterol was estimated by use of the Friedewald equation (29 ) . We measured interleukin-6 with an ultrasensitive ELISA from R&D Systems (30 ) and cystatin C concentrations with a BNII nephelometer (Siemens Healthcare Diagnostics); intraassay CVs were Յ3%. We used these measurements to calculate estimated glomerular filtration rate (eGFR) with the formula eGFRϭ 76.7 * cystatin C Ϫ1.19 (31 ) . We collected spot morning urine specimens, measured urine albumin and creatinine with nephelometry and the rate Jaffe reaction, respectively, and calculated urine albumin-to-creatinine ratios (mg /g) (32 ) . We used fasting morning blood samples to measure calcium and phosphorus with a Siemens Dimensions Vista 500 system. The limits of detection were 5 mg/dL (1.25 mmol/L) for serum calcium and 1.0 mg/dL (0.323 mmol/L) for serum phosphorus. CVs were Ͻ1% for serum calcium at 9.0 mg/dL (2.25 mmol/L) and serum phosphorus at 4.0 mg/dL (1.29 mmol/L).
STATISTICAL ANALYSIS
We categorized participants into quartiles by the distribution of fetuin-A and compared differences in baseline characteristics across quartiles. P values are for linear trend derived from linear regression models. Prevalent CAC was defined as a score Ͼ0 at baseline. We modeled the association of fetuin-A with prevalent CAC with relative risk regression, by use of a generalized linear model with log link, gaussian error, and robust standard errors (33, 34 ) . Given cross-sectional design, results are interpreted as prevalence ratios. We developed sequential models: model 1 was adjusted for age, sex, and race/ethnicity; model 2 added body mass index, diabetes, systolic blood pressure, blood pressure medication use, smoking (never, former, current), total cholesterol, HDL cholesterol, natural log of serum triglycerides, lipid medication use, and natural log of interleukin-6; and model 3 added eGFR, urine albumin-to-creatinine ratio, and serum calcium and phosphorus concentrations. Multiplicative interaction terms evaluated in model 3 tested for effect modification by sex, race, and diabetes status. We evaluated statistical significance of the interaction term by the likelihood ratio test comparing nested models with or without inclusion of the interaction term.
Among participants with detectable CAC at baseline, we assessed the relationship of fetuin-A with severity of CAC (natural log of CAC score) by use of multiple linear regression. The ␤ coefficient from linear regression was exponentiated, subtracted from 1, and multiplied by 100 to allow interpretation as the percentage difference in CAC severity per SD change in fetuin-A.
Incident CAC was defined as any CAC on follow-up CT among participants with CAC scores of 0 at the baseline visit. We used Poisson regression with a log-link, robust variance estimation, and an offset for time between CAC measurements. Among individuals with detectable CAC at baseline, we evaluated the relationship of fetuin-A with progression of CAC from the baseline CT to the follow-up CT with multiple linear regression. We evaluated the natural log of change in CAC score, and the ␤ coefficient was exponentiated, subtracted from 1, and multiplied by 100 to allow interpretation as the percentage change in CAC between examinations.
We performed statistical analyses using S-Plus 8.0 (Insightful Corp.) and Stata version 10.1 (Stata Corp.). P values Ͻ0.05 were considered statistically significant for all analyses including interaction terms.
Results
Among the 2457 study participants, the mean age was 62 (10) years and 52% were female. Forty percent were white, 27% were African-American, 20% were Hispanic, and 13% were Chinese. Twelve percent (n ϭ 488) had diabetes, and the mean eGFR was 94 (22) mL/min/1.73m 2 . The mean fetuin-A concentration was 0.48 (0.10) g/L. Twelve hundred participants (49%) had prevalent CAC at the baseline examination.
Participants with higher fetuin-A concentrations were younger, more frequently male and white, and less frequently African-American (Table 1) (Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/ vol58/issue5). Individuals with higher fetuin-A concentrations also had greater body mass indices; lower prevalence of diabetes but higher fasting insulin; lower systolic blood pressure and less use of blood pressure medications; higher total cholesterol, LDL cholesterol, and triglycerides; and lower interleukin-6, higher calcium, and lower phosphorus concentrations.
We observed a monotonic inverse association of fetuin-A with CAC prevalence in unadjusted analysis (Fig. 1) . Table 2 shows the association of fetuin-A with CAC prevalence in a series of adjusted models. In unadjusted models, compared with the lowest quartile, participants in the highest quartile had 15% lower prevalence of CAC, and each SD (0.10 g/L) of higher fetuin-A was associated with a 5% lower prevalence of CAC. This association was attenuated when adjusted for age, sex, and race; age accounted for most of the attenuation. With adjustment for traditional CVD risk factors (model 2) and kidney function, calcium, and phosphorus (model 3), a threshold effect was observed wherein the lowest fetuin-A quartile had the highest prevalence of CAC but the prevalence in quartiles 2 through 4 were all about 7% lower compared with the lowest quartile, although no quartile in isolation was significantly different from the lowest. When quartiles 2 through 4 were collapsed and compared to quartile 1 in the final model, individuals in quartiles 2 through 4 had 7% (95% CI 1%-13%; P ϭ 0.043) lower prevalence of CAC compared with quartile 1.
At the baseline examination, 1257 participants had CAC scores Ͼ0. Among these individuals, higher fetuin-A concentration was associated with progressively less severe CAC ( Fig. 1 and Table 3 ). Comparing extreme quartiles, participants in the highest quartile had 34% less severe CAC than the lowest quartile, and each SD of higher fetuin-A concentration was associated with 17% lesser CAC severity. This association was attenuated with adjustment for age, sex, and race. In models adjusted for traditional CVD risk factors (model 2) and kidney function, calcium, and phospho- rus (model 3), a monotonic inverse association of fetuin-A with CAC severity emerged again, such that in the final model, participants in the highest quartile had 26% lower CAC scores than the lowest quartile. Among the 1200 participants without CAC at the baseline examination, 272 individuals developed CAC on a follow-up CT scan performed a median 3.2 years (range 2.2-4.9 years) after baseline. Although the point estimates suggested associations in similar directions to the cross-sectional analyses described above, the association of fetuin-A with incident CAC was not statistically significant in any of the models (Table 4) . Among individuals with detectable CAC at baseline, 92% had greater CAC scores at the time of the follow-up CT scan. Individuals with higher fetuin-A concentrations at baseline were less likely to experience CAC progression in unadjusted analyses. However, although point estimates remained in the same direction, this association was also attenuated with adjustment for age, sex, and race and was not significant through the remaining sequence of adjusted models (Table 5) . Last, because point estimates suggested a possible asso- ciation of fetuin-A with CAC incidence and progression in Tables 4 and 5 , we evaluated a combined outcome [defined as Ln(CACϩ1) at the follow-up CT Ϫ Ln(CACϩ1)at the baseline CT] to maximize statistical power. In the fully adjusted model, we did not observe a statistically significant association of fetuin-A with this outcome (P ϭ 0.37).
We determined the association of fetuin-A [per SD (0.1g/L) greater] with % CAC severity among all individuals, and within strata defined by sex, race/ethnicity, and diabetes status (online Supplemental Fig.) . Although point estimates varied somewhat, none of the tests for interaction were statistically significant (all P interactions Ͼ0.20), nor were any interactions present for outcomes of CAC prevalence, incidence, or progression (all P interactions Ͼ0.05).
Discussion
Fetuin-A concentrations were inversely associated with CAC severity in a large multiethnic community-living population without clinically apparent CVD, independent of traditional CVD risk factors and kidney function. Results were similar irrespective of sex, race/ ethnicity, or diabetes status. Conversely, fetuin-A concentrations were not significantly associated with CAC incidence or progression over 3 years.
Prior studies have evaluated fetuin-A among ESRD patients and in select populations with prevalent clinical CVD. Findings have been conflicting, showing inverse, absent, and positive directions of associations (12, 13, (35) (36) (37) (38) , which may reflect differences in enrollment criteria and small sample sizes. To our knowl- Table 3 . Cross-sectional association of fetuin-A with percent severity of CAC: MESA.
Fetuin-A quartile
Per SD (0.10 g/L) of higher fetuin-A P 1 (<0.42 g/L) 2 (0.42-0.47 g/L) 3 (0.48-0.54 g/L) 4 Incident CAC/at risk, n (%) 62/281 (22 edge, only 1 prior study has examined the association of fetuin-A concentrations with CAC in communityliving individuals without advanced chronic kidney disease (CKD) or known clinical CVD. In a pilot study among older individuals in the Rancho Bernardo Study, we observed that fetuin-A concentrations were inversely associated with CAC severity (13 ) . These findings were considered preliminary, as only 28% of participants with available fetuin-A measurements had CT scans for CAC and the fetuin-A and CAC measurements were not concurrent (median time between measurement was 4.6 years). Moreover, compared with subjects evaluated here, the study sample was considerably older and exclusively white. These results are confirmed in a larger sample here, and extended to a younger, geographically and racially diverse cohort. The substantially larger sample size also allowed us to test heterogeneity by sex, race, and diabetes status: an important contribution, as prior studies have suggested that relationships may differ across these subgroups (12, 39 ) .
Whereas lower fetuin-A concentrations were independently associated with CAC severity, fetuin-A was only associated with CAC prevalence when we compared the lowest quartile with quartiles 2 through 4, and we did not observe statistically significant associations of fetuin-A with CAC incidence or progression over 3 years. Our study may have been underpowered to detect a small or moderate association of fetuin-A with these outcomes. Although the difference was not statistically significant, individuals with higher fetuin-A had lower point estimates for each. Future studies with larger sample sizes are required to determine whether the lack of statistical significance for these outcomes was due to insufficient statistical power or absent biological effects.
A priority for future research will be to definitively establish whether fetuin-A is associated with incident CVD events in community-living individuals. Unfortunately, at present, existing data regarding this question are also conflicting. In the largest study to date, Weikert et al. (40 ) evaluated 2593 middle-aged Europeans and reported that higher fetuin-A concentrations were associated with incident myocardial infarction and stroke. The direction of association reported in that study is surprising in light of our findings, as we report that individuals with higher fetuin-A concentrations had less severe CAC. Because higher fetuin-A concentrations may also induce peripheral insulin resistance, (41 ) it is possible that the mechanisms linking high fetuin-A with CVD events in the study by Weikert were through pathways distinct from arterial calcium deposition. In contrast, 2 other smaller studies have reported that lower fetuin-A concentrations measured in individuals with myocardial infarction were associated with greater mortality risk (42, 43 ) . Thus future studies are required to determine the direction of association of fetuin-A with the incident development of CVD events in community-living individuals and to evaluate the extent to which factors such as arterial calcification and insulin resistance may mediate or modify the association.
Our study has important limitations. Fetuin-A was measured at 1 point in time. To our knowledge, the a IQR to interquartile range; CAC progression to percent change in the Agatston score from baseline to follow-up CT scan among the subset of subjects with prevalent CAC (Agatston score Ͼ0) at the baseline examination. b Adjusted for age to sex to and race/ethnicity. c Adjusted for model 1 variables plus body mass index to diabetes to systolic blood pressure to blood pressure medication use to smoking (never to former to current) to total cholesterol to HDL cholesterol to natural log of triglycerides to lipid medication use to and natural log of interleukin-6. d Adjusted for model 2 variables plus eGFR to natural log of urine albumin-to-creatinine ratio to calcium to and phosphorus.
test-retest correlation of fetuin-A within individuals is unknown. Moreover, whether intraindividual changes in fetuin-A concentrations over time may provide additional information about risk of CAC prevalence, severity, incidence, and progression is an important question for future research. Participants were of 4 race/ethnicities and middle and older age, and prevalent clinical CVD was an exclusion criteria. Few participants had moderate or severe CKD. Our results may not generalize to these other populations.
In conclusion, serum fetuin-A concentrations are inversely associated with CAC severity independent of traditional CVD risk factors and kidney function in community-living individuals free of clinically apparent CVD. Future studies are required to determine the association of fetuin-A with incident CVD events and, if the association is observed, to determine whether diabetes or the presence of arterial calcification may mediate or modify the association.
